StockMacro
Menu

ABVC BioPharma

$0.87 -33% in 6 monthsMarket cap $23.4M

ABVC on XNAS, Health Care, ABVC BioPharma, Inc., job postings

Measures activity, not value. Not investment advice.

Cash stands at $66K against a $4.7M net loss, while shares fell 67% in 12 months.

  • Bad1 private offering filed in 90 days, which can bring new shares

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

Industry
Pharmaceutical preparations (Health Care)
Employees
19
Website
abvcpharma.com
Listed
Nasdaq, US
Last results
3 Mar 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net income $1.1M.
Quarter to 31 Dec 2021: revenue –, net income -$7.1MQuarter to 31 Mar 2022: revenue $26K, net income -$6.1MQuarter to 31 Mar 2022: revenue $26K, net income -$6.1MQuarter to 30 Jun 2022: revenue $313K, net income -$1.9MQuarter to 30 Jun 2022: revenue $313K, net income -$1.9MQuarter to 30 Sep 2022: revenue $42K, net income -$3.7MQuarter to 30 Sep 2022: revenue $42K, net income -$3.7MQuarter to 31 Dec 2022: revenue $589K, net income –Quarter to 31 Mar 2023: revenue $128K, net income -$1.8MQuarter to 31 Mar 2023: revenue $128K, net income -$1.8MQuarter to 30 Jun 2023: revenue $6K, net income -$2.3MQuarter to 30 Jun 2023: revenue $6K, net income -$2.3MQuarter to 30 Sep 2023: revenue $16K, net income -$3.3MQuarter to 30 Sep 2023: revenue $16K, net income -$3.3MQuarter to 31 Dec 2023: revenue $2K, net income -$3.1MQuarter to 31 Dec 2023: revenue $2K, net income -$3.1MQuarter to 31 Mar 2024: revenue $1K, net income -$3.9MQuarter to 31 Mar 2024: revenue $1K, net income -$3.9MQuarter to 30 Jun 2024: revenue $117K, net income -$1.3MQuarter to 30 Jun 2024: revenue $117K, net income -$1.3MQuarter to 30 Sep 2024: revenue $389K, net income -$187KQuarter to 30 Sep 2024: revenue $389K, net income -$187KQuarter to 31 Mar 2025: revenue –, net income -$842KQuarter to 30 Jun 2025: revenue –, net income -$2.3MQuarter to 30 Sep 2025: revenue –, net income -$1.2MQuarter to 31 Dec 2025: revenue –, net income -$3.6MQuarter to 31 Mar 2026: revenue –, net income -$1.6MQuarter to 30 Jun 2026: revenue –, net income -$737KQuarter to 30 Sep 2026: revenue –, net income $1.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $7.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–$1.1M
30 Jun 2026–-$737K
31 Mar 2026–-$1.6M
31 Dec 2025–-$3.6M
30 Sep 2025–-$1.2M
30 Jun 2025–-$2.3M
31 Mar 2025–-$842K
30 Sep 2024$389K-$187K
30 Jun 2024$117K-$1.3M
31 Mar 2024$1K-$3.9M
31 Dec 2023$2K-$3.1M
30 Sep 2023$16K-$3.3M
30 Jun 2023$6K-$2.3M
31 Mar 2023$128K-$1.8M
31 Dec 2022$589K–
30 Sep 2022$42K-$3.7M
30 Jun 2022$313K-$1.9M
31 Mar 2022$26K-$6.1M
31 Dec 2021–-$7.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$4.7M -$5.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.21 -$0.30
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -37.5% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $66K $257K
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $1.3M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – $1.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.48
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.8 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ABVC BioPharmaABVC (this company) $23.4Mloss–––
Incannex HealthcareIXHL $23.3Mloss–––
Rockwell MedicalRMTI $23.1Mloss0.32-4.0%-7.8%
ScynexisSCYX $23.7Mloss1.3+544%-53.5%
CervoMedCRVO $22.1Mlossover 999-100%–
Briacell TherapeuticsBCTX $26.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

4.9%

1.3M shares held by 13F filers (30 Sep 2026) of 27.0M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.2%

603K shares sold short (30 Oct 2026) of 27.0M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

19.9

603K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.2%

590K shares sold short in the report before, 603K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

22%

22% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 30%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

9 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.87 on 20 Nov 2026, -67% over 12 months (12-month range $0.71 to $2.71)

  • Sharp change
  • 8-K and other filings
Revenue per quarter. Revenue $389K in the latest quarter, +2351% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 14 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 20268-K and other filingsPrivate placement of securities (Form D)
2 Nov 20268-K and other filingsA major agreement ended
27 Aug 20268-K and other filingsCompleted an acquisition or asset sale
2 Jul 20268-K and other filingsChanged its auditor
15 May 20268-K and other filingsReport will be filed late
3 Mar 20268-K and other filingsEarlier financial statements can no longer be relied on
30 Oct 20258-K and other filingsDirector or officer change
30 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Apr 20258-K and other filingsDelisting notice or listing transfer
15 Apr 20258-K and other filingsEarlier financial statements can no longer be relied on
31 Mar 20258-K and other filingsReport will be filed late
7 Mar 20258-K and other filingsDirector or officer change
7 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Dec 2024Sharp changeShort interest spike: short interest spike, 628K vs usual 157K (2024-12-13); 13.4x the same period a year earlier
18 Oct 20248-K and other filingsChanged its auditor
23 Jul 20248-K and other filingsDirector or officer change
23 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jul 20248-K and other filingsDelisting notice or listing transfer
21 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
28 May 2024Sharp changeShort interest spike: short interest spike, 588K vs usual 108K (2024-05-15); 4.4x the same period a year earlier
28 May 20248-K and other filingsPrivate placement of securities (Form D)
15 May 20248-K and other filingsReport will be filed late
14 May 2024Sharp changeShort interest spike: short interest spike, 638K vs usual 108K (2024-04-30); 3.9x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 533K vs usual 108K (2024-04-15); 4.8x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 108K (2024-03-28); 10.9x the same period a year earlier
22 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
16 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
9 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
12 Jan 20248-K and other filingsRegistered new securities for sale (S-1)
16 Nov 20238-K and other filingsCompleted an acquisition or asset sale
14 Nov 2023Sharp changeShort interest spike: short interest spike, 984K vs usual 79K (2023-10-31); 60.2x the same period a year earlier
14 Nov 20238-K and other filingsReport will be filed late
31 Aug 20238-K and other filingsDelisting notice or listing transfer
23 Jun 20238-K and other filingsDirector or officer change
15 Jun 20238-K and other filingsDirector or officer change
15 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
7 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
1 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
26 May 20238-K and other filingsDelisting notice or listing transfer
10 May 20238-K and other filingsRegistered new securities for sale (S-1)
24 Apr 20238-K and other filingsRegistered new securities for sale (S-1)
2 Mar 20238-K and other filingsPrivate placement of securities (Form D)
16 Feb 20238-K and other filingsDelisting notice or listing transfer
21 Oct 20228-K and other filingsChanged its auditor
9 Sep 20228-K and other filingsDirector or officer change
22 Aug 20228-K and other filingsDelisting notice or listing transfer
14 Jul 20228-K and other filingsDirector or officer change
1 Jun 20228-K and other filingsDirector or officer change
1 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Revenue per quarter
Quarter ended 31 Mar 2022: $26K, -90% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $313K, +895% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $42K, -57% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $589K; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $128K, +400% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $6K, -98% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $16K, -62% on a year earlier; public on 16 Nov 2023
Quarter ended 31 Dec 2023: $2K, -100% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $1K, -99% on a year earlier; public on 18 May 2024
Quarter ended 30 Jun 2024: $117K, +1818% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $389K, +2351% on a year earlier; public on 15 Nov 2024
Capital spending per quarter
Quarter ended 31 Dec 2021: $0; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $93K; public on 17 May 2022
Quarter ended 30 Jun 2022: $22K; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $4K; public on 16 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 14 Mar 2024
Institutional holders (13F filers)
31 Dec 2021 report: 4; public on 14 Feb 2022
31 Mar 2022 report: 4; public on 16 May 2022
30 Jun 2022 report: 5; public on 15 Aug 2022
30 Sep 2022 report: 10; public on 14 Nov 2022
31 Dec 2022 report: 9; public on 14 Feb 2023
31 Mar 2023 report: 8; public on 15 May 2023
30 Jun 2023 report: 8; public on 14 Aug 2023
30 Sep 2023 report: 7; public on 14 Nov 2023
31 Dec 2023 report: 8; public on 14 Feb 2024
31 Mar 2024 report: 8; public on 15 May 2024
30 Jun 2024 report: 11; public on 14 Aug 2024
30 Sep 2024 report: 9; public on 14 Nov 2024
31 Dec 2024 report: 13; public on 14 Feb 2025
31 Mar 2025 report: 10; public on 15 May 2025
30 Jun 2025 report: 8; public on 14 Aug 2025
30 Sep 2025 report: 14; public on 14 Nov 2025
31 Dec 2025 report: 14; public on 17 Feb 2026
31 Mar 2026 report: 13; public on 15 May 2026
30 Jun 2026 report: 15; public on 14 Aug 2026
30 Sep 2026 report: 14; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is days to cover (short interest / average daily volume, as published by FINRA) at 19.9 (30 Oct 2026), 5.6× its normal reading; higher than 100% of its own history.
  • Revenue per quarter: Revenue $389K in the latest quarter, +2351% on a year earlier.
  • Capital spending per quarter: Capital spending $0 in the latest quarter.
  • Institutional holders (13F filers): 14 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

14 institutions reported shares at the end of Q3 2026, 5% of the shares outstanding; 3 opened a position, 4 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Vanguard Capital Management LLC569K2.11%$603K+195K+52%
Geode Capital Management, LLC237K0.88%$251K+8,692+3.8%
UBS Group AG139K0.52%$148K+105K+308%
Vanguard Fiduciary Trust Co97K0.36%$103KNo change
State Street Corp91K0.34%$97K+18K+25%
BlackRock, Inc.56K0.21%$60KNo change
Northern Trust Corp49K0.18%$52KNo change
Panagora Asset Management Inc37K0.14%$39KNo change
Citadel Advisors LLC29K0.11%$31K-43K-59%
Squarepoint Ops LLC11K0.04%$12KNew+11K

In 12 months: 2 major agreements, 1 restatement warning, 1 late report, 1 auditor change. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Nov 2026Private placement of securities (Form D)$3.4M sold of $3.4M offeredD
2 Nov 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately, shareholder vote results8-K
27 Aug 2026Signed a major agreement; Completed an acquisition or asset sale8-K
2 Jul 2026Changed its auditor8-K
15 May 2026Quarterly report will be filed lateNT 10-Q
3 Mar 2026Earlier financial statements can no longer be relied on8-K
30 Oct 2025Director or officer change8-K
30 Apr 2025Delisting notice or listing transferSame filing: sold shares privately8-K
Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Filings record

    Private placement of securities (Form D)

  2. 2 Nov 2026Filings record

    A major agreement ended

  3. 27 Aug 2026Filings record

    Completed an acquisition or asset sale

  4. 2 Jul 2026Filings record

    Changed its auditor

  5. 15 May 2026Filings record

    Report will be filed late

  6. 3 Mar 2026Filings record

    Earlier financial statements can no longer be relied on

  7. 30 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 30 Oct 2025Filings record

    Director or officer change

  9. 30 Apr 2025Filings record

    Delisting notice or listing transfer

  10. 15 Apr 2025Filings record

    Earlier financial statements can no longer be relied on

  11. 31 Mar 2025Filings record

    Report will be filed late

  12. 7 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 7 Mar 2025Filings record

    Director or officer change

  14. 25 Dec 2024Short interest and volume change

    had 628K shares sold short in the 13 Dec 2024 report, 13× the same report last year.

    Same report last year: 47K; its normal report is 157K.

    See the evidence
    This period
    628K (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    157K
    Typical spread (median absolute deviation)
    49K
    How far from its usual level
    +6.5
    Same report last year
    47K
    History used
    2,312 days
    2023-12-15: 47K2023-12-29: 16K2024-01-12: 132K2024-01-31: 124K2024-02-15: 121K2024-02-29: 151K2024-03-15: 106K2024-03-28: 1.3M2024-04-15: 533K2024-04-30: 638K2024-05-15: 588K2024-05-31: 435K2024-06-14: 370K2024-06-28: 228K2024-07-15: 163K2024-07-31: 180K2024-08-15: 127K2024-08-30: 138K2024-09-13: 111K2024-09-30: 132K2024-10-15: 138K2024-10-31: 186K2024-11-15: 334K2024-11-29: 253K2024-12-13: 628K
    the 13 Dec 2024 report24 earlier reportsnormal: 157K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 18 Oct 2024Filings record

    Changed its auditor

  16. 23 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 23 Jul 2024Filings record

    Director or officer change

  18. 12 Jul 2024Filings record

    Delisting notice or listing transfer

  19. 21 Jun 2024Filings record

    Registered new securities for sale (S-1)

  20. 28 May 2024Filings record

    Private placement of securities (Form D)

  21. 25 May 2024Short interest and volume change

    had 588K shares sold short in the 15 May 2024 report, 4.4× the same report last year.

    Same report last year: 135K; its normal report is 108K.

    See the evidence
    This period
    588K (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +5.8
    Same report last year
    135K
    History used
    2,100 days
    2023-05-15: 135K2023-05-31: 84K2023-06-15: 111K2023-06-30: 75K2023-07-14: 58K2023-07-31: 176K2023-08-15: 28K2023-08-31: 20K2023-09-15: 19K2023-09-29: 14K2023-10-13: 34K2023-10-31: 984K2023-11-15: 88K2023-11-30: 114K2023-12-15: 47K2023-12-29: 16K2024-01-12: 132K2024-01-31: 124K2024-02-15: 121K2024-02-29: 151K2024-03-15: 106K2024-03-28: 1.3M2024-04-15: 533K2024-04-30: 638K2024-05-15: 588K
    the 15 May 2024 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 15 May 2024Filings record

    Report will be filed late

  23. 10 May 2024Short interest and volume change

    had 638K shares sold short in the 30 Apr 2024 report, 3.9× the same report last year.

    Same report last year: 163K; its normal report is 108K.

    See the evidence
    This period
    638K (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +6.8
    Same report last year
    163K
    History used
    2,085 days
    2023-04-28: 163K2023-05-15: 135K2023-05-31: 84K2023-06-15: 111K2023-06-30: 75K2023-07-14: 58K2023-07-31: 176K2023-08-15: 28K2023-08-31: 20K2023-09-15: 19K2023-09-29: 14K2023-10-13: 34K2023-10-31: 984K2023-11-15: 88K2023-11-30: 114K2023-12-15: 47K2023-12-29: 16K2024-01-12: 132K2024-01-31: 124K2024-02-15: 121K2024-02-29: 151K2024-03-15: 106K2024-03-28: 1.3M2024-04-15: 533K2024-04-30: 638K
    the 30 Apr 2024 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Apr 2024Short interest and volume change

    had 533K shares sold short in the 15 Apr 2024 report, 4.8× the same report last year.

    Same report last year: 112K; its normal report is 108K.

    See the evidence
    This period
    533K (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +6.1
    Same report last year
    112K
    History used
    2,070 days
    2023-04-14: 112K2023-04-28: 163K2023-05-15: 135K2023-05-31: 84K2023-06-15: 111K2023-06-30: 75K2023-07-14: 58K2023-07-31: 176K2023-08-15: 28K2023-08-31: 20K2023-09-15: 19K2023-09-29: 14K2023-10-13: 34K2023-10-31: 984K2023-11-15: 88K2023-11-30: 114K2023-12-15: 47K2023-12-29: 16K2024-01-12: 132K2024-01-31: 124K2024-02-15: 121K2024-02-29: 151K2024-03-15: 106K2024-03-28: 1.3M2024-04-15: 533K
    the 15 Apr 2024 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Apr 2024Short interest and volume change

    had 1.3M shares sold short in the 28 Mar 2024 report, 11× the same report last year.

    Same report last year: 121K; its normal report is 108K.

    See the evidence
    This period
    1.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    38K
    How far from its usual level
    +21.4
    Same report last year
    121K
    History used
    2,052 days
    2023-03-31: 121K2023-04-14: 112K2023-04-28: 163K2023-05-15: 135K2023-05-31: 84K2023-06-15: 111K2023-06-30: 75K2023-07-14: 58K2023-07-31: 176K2023-08-15: 28K2023-08-31: 20K2023-09-15: 19K2023-09-29: 14K2023-10-13: 34K2023-10-31: 984K2023-11-15: 88K2023-11-30: 114K2023-12-15: 47K2023-12-29: 16K2024-01-12: 132K2024-01-31: 124K2024-02-15: 121K2024-02-29: 151K2024-03-15: 106K2024-03-28: 1.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 22 Mar 2024Filings record

    Registered new securities for sale (S-1)

  27. 16 Feb 2024Filings record

    Registered new securities for sale (S-1)

  28. 9 Feb 2024Filings record

    Registered new securities for sale (S-1)

  29. 12 Jan 2024Filings record

    Registered new securities for sale (S-1)

  30. 16 Nov 2023Filings record

    Completed an acquisition or asset sale

  31. 14 Nov 2023Filings record

    Report will be filed late

  32. 10 Nov 2023Short interest and volume change

    had 984K shares sold short in the 31 Oct 2023 report, 60× the same report last year.

    Same report last year: 16K; its normal report is 79K.

    See the evidence
    This period
    984K (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    79K
    Typical spread (median absolute deviation)
    49K
    How far from its usual level
    +12.5
    Same report last year
    16K
    History used
    1,903 days
    2022-10-31: 16K2022-11-15: 33K2022-11-30: 37K2022-12-15: 37K2022-12-30: 28K2023-01-13: 289K2023-01-31: 112K2023-02-15: 108K2023-02-28: 163K2023-03-15: 146K2023-03-31: 121K2023-04-14: 112K2023-04-28: 163K2023-05-15: 135K2023-05-31: 84K2023-06-15: 111K2023-06-30: 75K2023-07-14: 58K2023-07-31: 176K2023-08-15: 28K2023-08-31: 20K2023-09-15: 19K2023-09-29: 14K2023-10-13: 34K2023-10-31: 984K
    the 31 Oct 2023 report24 earlier reportsnormal: 79K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 31 Aug 2023Filings record

    Delisting notice or listing transfer

  34. 23 Jun 2023Filings record

    Director or officer change

  35. 15 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 15 Jun 2023Filings record

    Director or officer change

  37. 8 Jun 2023Filings record

    Registered new securities for sale (S-1)

  38. 7 Jun 2023Filings record

    Registered new securities for sale (S-1)

  39. 1 Jun 2023Filings record

    Registered new securities for sale (S-1)

  40. 26 May 2023Filings record

    Delisting notice or listing transfer

Showing the newest 40 of 99 entries; narrow the window or the kind of data to see older ones.

Not listed: 118 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001173313
Ticker
ABVC
Domain
abvcpharma.com
Hq location
CA|FREMONT|94538 (1 unverified)
Name
ABVC BioPharma, Inc., AiBtl BioPharma Inc, American BriVision Corporation, American BriVision (Holding) Corp and 9 more
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)204 records12 Feb 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)899 data points30 Jun 2010 to 9 Nov 2026
  • FINRA short interest (twice monthly)483 data points15 Aug 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2664 data points3 Aug 2021 to 20 Nov 2026